C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value
$2.76−0.01 (-0.36%)
Close on Nov 13, 2026Market cap $339.55MP/E –Yield –
C4 Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
C4 Therapeutics's price to book ratio was 1.4× on Nov 11, 2026, against 1.3× a year earlier. Over the last 5 years it ranged from 0.3× to 3.9×, with a median of 1.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.4× | +0.5 |
| 2025 | Dec 31, 2025 | 0.9× | −0.1 |
| 2024 | Dec 31, 2024 | 1.0× | −0.2 |
| 2023 | Dec 29, 2023 | 1.3× | +0.4 |
| 2022 | Dec 30, 2022 | 0.9× | −3.0 |
| 2021 | Dec 31, 2021 | 3.9× | – |
See a number that looks wrong?